Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy

NCT02987985 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-08-10

No results posted yet for this study

Summary

The objective of this trial is to determine whether an opioid-free general anesthetic (OFA) technique utilizing ketamine, dexmedetomidine, lidocaine, and gabapentin can help reduce postoperative respiratory depression in the post-anesthesia care unit and ward in children with sleep-disordered breathing undergoing tonsillectomy when compared with traditional opioid-containing techniques. It is expected that this OFA regimen will have a measurable reduction on postoperative respiratory depression in children with sleep-disordered breathing.

Conditions

  • Anesthesia
  • General Anesthesia
  • Analgesics, Opioid
  • Postoperative Complications
  • Pathologic Processes
  • Physiologic Effects of Drugs
  • Narcotics
  • Analgesics
  • Sleep Disordered Breathing
  • Obstructive Sleep Apnea of Child
  • Tonsillectomy
  • Respiratory Depression
  • Dexmedetomidine
  • Ketamine
  • Lidocaine
  • Gabapentin
  • Pulse Oximetry

Interventions

DRUG

Acetaminophen, gabapentin

acetaminophen 15 mg/kg, gabapentin 10 mg/kg

DRUG

Acetaminophen

acetaminophen 15 mg/kg

DRUG

Ketamine , Lidocaine , Dexmedetomidine

Ketamine 0.5 mg/kg, Lidocaine 1 mg/kg, Dexmedetomidine 0.3 mcg/kg

DRUG

Fentanyl, Dexmedetomidine

Fentanyl 0.5 mcg/kg, Dexmedetomidine 0.3 mcg/kg

DRUG

Dexamethasone , Ondansetron

Dexamethasone 150 mcg/kg, Ondansetron 50 mg/kg

DRUG

Sevoflurane

Sevoflurane (dose titrated to effect)

DRUG

Sevoflurane, Fentanyl

Sevoflurane (dose titrated to effect), Fentanyl as needed (dose at anesthesiologist's discretion)

Sponsors & Collaborators

  • University of Saskatchewan

    lead OTHER

Principal Investigators

  • Jon Gamble, MD · University of Saskatchewan

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-15
Primary Completion
2019-09-20
Completion
2020-12-20

Countries

  • Canada

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02987985 on ClinicalTrials.gov